Pro Share Advisors LLC Tcr2 Therapeutics Inc. Transaction History

Pro Share Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$2.4 - $4.71 $28,905 - $56,727	-12,044 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$4.58 - $8.34 $146 - $266	-32 Reduced 0.26%	12,044 $56,000
Q3 2021 Nov 12, 2021	SELL	$8.44 - $18.35 $22,745 - $49,453	-2,695 Reduced 18.25%	12,076 $103,000
Q2 2021 Aug 13, 2021	BUY	$16.41 - $24.71 $29,127 - $43,860	1,775 Added 13.66%	14,771 $242,000
Q1 2021 May 14, 2021	BUY	$20.38 - $34.07 $45,080 - $75,362	2,212 Added 20.51%	12,996 $287,000

Q4 2020 Feb 09, 2021	BUY	$19.0 - $32.63 $204,896 - $351,881	10,784 New	10,784 $334,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.